Abbott (ABT) Q3 FY25 earnings call

Abbott delivered a strong Q3 FY25, driven by robust performance in Medical Devices and Established Pharmaceuticals, despite headwinds in China Diagnostics and U.S. Pediatric Nutrition. The company remains confident in its ability to sustain high single-digit top-line and double-digit EPS growth into FY26, fueled by new product launches and easing prior-year comparables. Management emphasized continued investment in its pipeline and a resilient, diversified portfolio.